Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6408 posts found.

sanofi_hq__boetie_hall_small_

Sanofi’s NSCLC drug gains EC approval

June 25, 2021 Medical Communications EC, EU, NSCLC, Sanofi

The European Commission (EC) has approved Sanofi and Regeneron’s PD-1 inhibitor, Libtayo (cemiplimab), for the first-line treatment of adults with …
News

Breakthrough announced in circulating tumour cell research

June 18, 2021 Medical Communications Cancer, Circulating tumour cells, Precision Medicine, oncology

Liquid biopsy company, Angle, has announced results from their study in non-small cell lung cancer (NSCLC) which demonstrates the benefit …
News

UK AI firm wins share of £140 million funding for lung cancer detection tech

June 18, 2021 Medical Communications AI, CT, NHS, funding, lunch cancer, screening, technology

Artificial intelligence firm Behold.ai has won a share of £140 million in government funding for its red dot lung cancer …
News
astrazeneca_plaque

Australia pauses AstraZeneca vaccine for people under 60

June 18, 2021 Medical Communications AstraZeneca, Australia, COVID-19, Vaccine

Australia will now only recommend that people over 60 receive the AstraZeneca vaccine due to the rare occurrence of post-jab …
News

New class of cancer-killing drugs identified

June 18, 2021 Medical Communications Cancer, oncology

Scientists have announced the identification of a new class of cancer drugs, known as POLQ inhibitors, that specifically kill cancer …
News

NICE recommends two new treatments for inflammatory arthritis

June 18, 2021 Medical Communications Eli Lilly, NICE, Novartis

NICE has recommended two new treatments for axial spondyloarthritis, an underdiagnosed and debilitating type of inflammatory arthritis. Ixekizumab (also known …
News

Third FDA panel member quits over controversial Alzheimer’s drug approval

June 11, 2021 Medical Communications

The third FDA advisory panel member has quit over the approval of a controversial new Alzheimer’s drug. Biogen’s drug, aducanumab, …
News

“The future of pain care”: Virtual reality therapy proven to aid chronic pain

June 11, 2021 Medical Communications CBT, Virtual reality, chronic pain management, technology

A novel digital therapeutics software, DTxP, has shown statistically significant benefits for patients with chronic low back pain (CLBP) in …
News

G7: UK to donate 100 million surplus vaccine doses

June 11, 2021 Medical Communications Boris Johnson, COVID-19, G7, Joe Biden, UK, US, Vaccine

Boris Johnson has announced at the G7 meeting in Cornwall that the UK will donate over 100 million surplus doses …
News
sanofi_hq__boetie_hall_web

Sutimlimab meets primary endpoint in treating cold agglutinin disease

June 11, 2021 Medical Communications

A Phase III study evaluating the safety and efficacy of sutimlimab in people with cold agglutinin disease (CAD) met its …
News
top_10_image_2_9

Pharmafile.com’s top 10 news stories of the week

June 11, 2021 Medical Communications

Among our ten most-read stories this week: AstraZeneca vs GSK: Cancer drug court battle could cost hundreds of millions; New …
News
top_10_image_2_9

Pharmafile.com’s top 10 news stories of the week

June 4, 2021 Medical Communications

Among our ten most-read stories this week: NICE rejects risdiplam for treating spinal muscular atrophy; The EU wants to Fine …
News
novartis_window

Novartis’s 177Lu-PSMA-617 reduces prostate cancer death risk by 38%

June 4, 2021 Medical Communications

Novartis’s 177Lu-PSMA-617 has shown to significantly improve overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer …
News

BMS announce new positive data from oesophageal cancer study

June 4, 2021 Medical Communications Cancer, oncology

Bristol Myers Squibb (BMS) has announced results from the Phase III CheckMate -648 trial in which nivolumab plus chemotherapy and …
News

Phase III trial shows Olaparib reduces breast cancer recurrence by 42%

June 4, 2021 Medical Communications

Results from OlympiA’s Phase III trial has shown that its Olaparib (Lynparza) in the adjuvant treatment of patients with germline …
News
The Gateway to Local Adoption Series

Latest content

Rhythm AI’s STAR Apollo system receives FDA clearance for atrial fibrillation

February 12, 2026

iOrganBio appoints Karol Jarzabek as Chief Operating Officer

February 12, 2026

Ensera Design expands UK leadership team with new senior appointments

February 11, 2026

Infinitopes announces $15.4m in additional seed funding to advance cancer vaccine

February 11, 2026

Angelini Pharma appoints Roberto Scrivo as Chief of External Affairs, Communication and Sustainability Officer

February 10, 2026